Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 12NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Ganglioneuroblastoma 1

Interventions

Dexamethasone 33Cyclophosphamide 28Melphalan 26Specimen Handling 24Biopsy 24Bortezomib 23Magnetic Resonance Spectroscopy 17Calcium Dobesilate 17fludarabine phosphate 15Lenalidomide 15Filgrastim 15Vincristine 12Prednisone 12Peripheral Blood Stem Cell Transplantation 12sargramostim 9dexamethasone acetate 9dexamethasone 21-phosphate 9carfilzomib 9auricularum 9Doxorubicin 9fludarabine 8Thalidomide 8Interferon-alpha 7Cyclosporine 7Busulfan 7trametinib 6Rituximab 6Etoposide 6ixazomib 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Multiple Myeloma × Leukapheresis × Clear all
NCT02728102 2024-05-07

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
203 enrolled 25 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡